ReNeuron Group plc CTX-iPSC platform data shows commerical potential
19 Noviembre 2021 - 1:00AM
RNS Non-Regulatory
TIDMRENE
ReNeuron Group plc
19 November 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
New CTX-iPSC platform data shows potential in Peripheral Nerve
Repair
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, announces that new data
relating to its CTX-derived induced Pluripotent Stem Cell
("CTX-iPSC") platform has been presented this week, showing their
commercial potential for the development of mass-scale therapeutics
for peripheral nerve repair.
The data has been presented at the 6th world congress of the
Tissue Engineering and Regenerative Medicine International Society
(TERMIS2021), a leading scientific conference taking place in
Maastricht, Netherlands.
Ms Rebecca Powell from the University College London ('UCL')
Centre for Nerve Engineering presented new data showing for the
first time that ReNeuron's CTX-iPSCs can be differentiated to
produce Schwann cells, a specific type of support cell that
promotes the survival and function of peripheral nerves and
importantly, when present in the appropriate three-dimensional
configuration, could promote the regrowth of nerve axons damaged by
traumatic injury, thus hopefully resulting in the regain of lost
functions. The conditional immortalisation cassette present in
CTX-iPSCs also promotes a much higher survival of mature Schwann
cells.
The abstract from the conference can be found here:
https://insight.klinkhamergroup.com/termis2021/book/abstract/878
Professor Stefano Pluchino, Chief Scientific Officer at
ReNeuron, commented: "These independently generated results are
particularly encouraging as they support the idea that ReNeuron's
CTX-iPSCs, initially reprogrammed from a proprietary, conditionally
immortalised, well-characterised, clinical grade neural stem cell
line, may allow for the potential to scale production of 'off the
shelf' allogeneic tissue engineered therapeutics. This makes them a
feasible mass-scale solution for areas such as peripheral nerve
repair."
Background
The Company has previously presented data demonstrating that its
proprietary human CTX neural stem cell line can be successfully and
rapidly reprogrammed to a pluripotent, embryonic stem cell-like
state enabling differentiation into any cell type. In essence, this
means that the Company is able to take its neural stem cells back
to being stem cells that can be made to develop into any other type
of cell in the body, including bone, nerve, muscle and skin.
Furthermore, CTX-iPSCs also hold the remarkable potential of
permitting the scalable manufacture of adult stem cells or tissue
progenitor populations for cell therapy.
ENDS
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Catherine Isted, Chief Financial Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker) +44 (0)20 7710 7600
Ben Maddison, Stewart Wallace
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus, Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments for disease with significant unmet
needs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the central nervous system and other disorders. The
Company also has the ability through its conditionally immortalised
induced pluripotent stem cell (iPSC) platform to make allogeneic
tissue cells of choice; in-house programmes are currently focused
on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFZMMMZRZGMZZ
(END) Dow Jones Newswires
November 19, 2021 02:00 ET (07:00 GMT)
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De May 2023 a May 2024